Clinical trial · Interventional
Effects of Wet-Cupping on Polycystic Ovary Syndrome Patients
Effects of Wet-Cupping on Polycystic Ovary Syndrome Patients: A Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to evaluate whether wet cupping therapy (Hijama) can improve reproductive and metabolic outcomes in women diagnosed with Polycystic Ovary Syndrome (PCOS). This study will be conducted among female participants aged 20-40 years who have been diagnosed with PCOS according to the Rotterdam criteria. The main questions it aims to answer are: Can wet cupping therapy regulate menstrual cycles in women with PCOS? Can it increase the pregnancy rate in married participants with PCOS-related infertility? Researchers will compare outcomes between a wet cupping group and a control group to determine whether Hijama has significant effects on reproductive, hormonal, and metabolic markers. Participants will: Undergo screening and eligibility evaluation using a checklist Be randomized into either the wet cupping (intervention) or control group Receive lifestyle counseling (diet and physical activity) For the intervention group: Receive one Hijama session performed by a certified practitioner Undergo follow-up at 4 and 12 weeks for clinical, hormonal, and ultrasound assessments For all participants: Complete laboratory tests, ultrasound scans, and questionnaires on PCOS symptoms and quality of life Report any side effects during and after the study period
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovarian Syndrome (PCOS) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Wet-cupping | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Hijama Group
- interventionNames
- Procedure: Wet-cupping
- type
- NO_INTERVENTION
- label
- Control Group
Primary outcomes (5)
- measure
- Change in Menstrual Cycle Duration
- timeFrame
- 12 weeks
- description
- This outcome refers to the change in the length of the entire menstrual cycle, measured in days, defined as the time from the first day of one menstrual period to the first day of the next. This measure reflects the regularity and timing of menstrual cycles, which are commonly disrupted in patients with Polycystic Ovary Syndrome (PCOS). Data will be collected through a structured self-report questionnaire administered at baseline and again at 12 weeks post-intervention. The difference in reported cycle length will be analyzed to evaluate the effect of wet cupping (Hijama) therapy on menstrual cycle regulation. This outcome aims to provide insight into the potential therapeutic impact of the intervention on menstrual irregularities, a hallmark clinical feature of PCOS.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria * Female participants. * Aged 20 to 40 years. * Diagnosed with Polycystic Ovary Syndrome (PCOS) according to the Rotterdam criteria. * Willing to participate in the study and provide informed consent. * Not using any of the following in the last month: (Hormonal medications for menstruation, Herbal menstrual remedies or Metformin). Exclusion Criteria * Known diagnosis of uncontrolled thyroid dysfunction. * Diagnosis of diabetes mellitus. * Elevated FSH levels above 20 mIU/mL. * Hyperprolactinemia with serum levels above 1000 mIU/L. * Pregnant or lactating women. * Known coagulation disorders. * Anemia with hemoglobin levels less than 10 g/dL. * History of undergoing dry cupping, wet cupping, or acupuncture in the past 6 months. * History of surgical removal of both ovaries or the uterus. * Other causes of hyperandrogenism, including: * Late-onset non-classic 21-hydroxylase deficiency (excluded clinically; lab investigation if clinically indicated). * Ovarian androgen-secreting tumors. * Use of anabolic or androgenic drugs. * Cushing's syndrome. * Hypothalamic or pituitary disorders causing amenorrhea. * Primary ovarian insufficiency.
References
Publications (0)
Data not yet available